Trial · NCT05155189
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
NCT05155189, Phase 1, Recruiting, Zhejiang University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma. Trials, record NCT05155189. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05155189
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
- NCT number
- NCT05155189
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 72 participants, estimated
- Lead sponsor
- Zhejiang University
- Conditions
- Hepatocellular Carcinoma
- Interventions
- C-CAR031, Lenvatinib, Regorafenib (BAY 73-4506), Durvalumab
- First posted
- 2021-12-13
- Last updated
- 2026-01-21
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | TEAEs | start pretreatment to 12 months | treatment emergent adverse events |
| Primary | AESIs | start pretreatment to 12 months | adverse events of special interest |
| Secondary | objective response rate by RECIST 1.1 | at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion | objective response rate according to RECIST 1.1 |
| Secondary | disease control rate by RECIST 1.1 | at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion | disease control rate according to RECIST 1.1 |
| Secondary | duration of response by RECIST 1.1 | at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion | duration of response according to RECIST 1.1 |
| Secondary | progression-free survival by RECIST 1.1 | The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.- | progression-free survival to RECIST 1.1 |
| Secondary | objective response rate by mRECIST | The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.- | objective response rate according to mRECIST |
| Secondary | disease control rate by RECIST | The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.- | disease control rate according to mRECIST |
| Secondary | duration of response by mRECIST | The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.- | duration of response according to mRECIST |
| Secondary | progression-free survival by mRECIST | The efficacy is evaluated at Weeks 6, 12, and 18 and Months 6, 9, and 12 after cell infusion.- | progression-free survival to mRECIST |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05155189
GET https://conductscience.org/api/trials/v1/NCT05155189/registered